AXON’s Pioneering Tau Vaccine against Alzheimer’s Started Phase II

BRATISLAVA, Slovakia–(BUSINESS WIRE)–AXON Neuroscience announced the successful start of the ADAMANT phase II study, as the first patient has been vaccinated with the active tau vaccine. AXON’s vaccine, AADvac1, is intended to be the first disease-modifying tau vaccine for Alzheimer’s disease. ADAMANT PHASE II CLINICAL STUDY ADAMANT is a 24-month, randomized, placebo-controlled, parallel group, double-blinded, multi-centre, phase II study to assess the safety and efficacy of AADvac1 applied to patients with mild Alzheimer’s disease. The primary objective is to confirm the positive phase I results by assessing safety and immunogenicity on a larger patient population with mild Alzheimer’s disease. The secondary objective is to evaluate the efficacy of the AADvac1 vaccine in slowing down or halting cognitive decline in patients over a period of 24 months. The study is powered…


Link to Full Article: AXON’s Pioneering Tau Vaccine against Alzheimer’s Started Phase II